X0609 4 2026-10-19 0001672619 Enliven Therapeutics, Inc. ELVN 0001882764 Hohl Benjamin false C/O ENLIVEN THERAPEUTICS, INC. 205 PARK ROAD BURLINGAME CA 94010 false true false false CHIEF FINANCIAL OFFICER 1 Common Stock 2026-10-19 4 M 0 6018 14.85 A 44018 D Common Stock 2026-10-19 4 S 0 6018 38.4755 D 38000 D Stock Option (right to buy) 14.85 2026-10-19 4 M 0 6018 0 D 2034-02-13 Common Stock 6018 175000 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter. /s/ Benjamin Hohl 2026-10-21